Botulinum toxin for scalp dysesthesia

Phan, Kevin; Lin, Matthew J

doi:10.4103/jcas.jcas_197_20

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are consistent with previous reports of the successful use of off-label BTX as a potential treatment modality for patients struggling with trichodynia [5,7]. Trimboli et al pioneered the first use of BTX for the treatment of trichodynia and relied on a dose of 200 units.…”

Section: Discussionsupporting

confidence: 92%

“…Off-label BTX has been shown in multiple, randomized, placebo-controlled studies to be an effective treatment modality in the management of various neuropathic disorders including plantar fasciitis, focal painful neuropathies, mechanical allodynia, and myofascial pain [12][13][14]. It has been postulated that BTX may directly inhibit neurogenic inflammation via an inhibitory effect on the release of various neurotransmitters from afferent nerve fibers responsible for eliciting the pain sensation including substance-P, calcitonin gene-related peptide, and glutamate [5,7,[12][13][14]. The exact mechanism of action of BTX in diminishing the pain response is yet to be fully understood.…”

Section: Discussionmentioning

confidence: 99%

“…Trichodynia can be both distressing for the patient and challenging for the clinician to treat, with no treatments currently available that are approved by the Food and Drug Administration (FDA) [5,7]. Furthermore, conventional therapies may predispose the patient to unwanted side effects [8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Successful Treatment of Refractory Trichodynia With Onabotulinumtoxin-A

Alhomida,

Alkhezzi,

Alshammari

et al. 2024

Cureus

View full text Add to dashboard Cite

Trichodynia is a common symptom, which is characterized by a painful, burning or stinging sensation of the scalp, often in patients presenting with hair loss. It is typically associated with co-morbid psychiatric conditions and remains challenging to treat, with no Food and Drug Administration (FDA) treatments currently available. We herein report the successful use of off-label onabotulinumtoxin-A in treating a patient with trichodynia who has failed conventional therapies.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment of Refractory Trichodynia With Onabotulinumtoxin-A

Alhomida,

Alkhezzi,

Alshammari

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…We identified 2 case reports describing 2 patients with scalp pain treated with BTX-A. 28,29 In one patient with diffuse scalp dysesthesia, split-scalp injections of BTX-A (40 units) and normal saline resulted in less pain on the side treated with BTX-A at the 8-week follow-up, although improved symptoms of both scalp hemispheres were noted. 28 Another patient with multiple painful cutaneous piloleiomyomas noted a rapid decrease in pain after injections with BTX-A (200 units) every 3 months.…”

Section: Scalp Painmentioning

confidence: 99%

Botulinum Toxin for Scalp Conditions: A Systematic Review

2023

View full text Add to dashboard Cite

BACKGROUND Many reports have described the use of botulinum toxin (BTX) in the treatment of scalp conditions, but no studies have synthesized these collective findings. OBJECTIVE We conducted a systematic review to summarize the scalp conditions for which treatment with BTX has been described. METHODS We searched PubMed/MEDLINE and Scopus for articles in English published before November 1, 2022, using the keywords “hair” or “scalp” and BTX-related search terms. Articles that described patients who received injections of BTX for the management of scalp conditions were included. RESULTS Twenty-four original articles (12 case reports, 9 clinical trials, and 3 case series) were identified that described 309 patients with a scalp condition treated with BTX. Androgenetic alopecia, craniofacial hyperhidrosis, and scalp hyperseborrhea had the most robust data supporting the clinical efficacy of BTX. CONCLUSION The current quality of evidence is highly variable and, for many conditions, limited to small observational studies. Botulinum toxin may be a promising therapeutic option for patients with various scalp conditions, but future studies are needed to better understand its efficacy and safety.

show abstract

“…The mechanism of action of BoNT-A is presumably due to blocking the release of acetylcholine from peripheral nerves, thereby reducing vasodilatation of the cutaneous blood vessels [ 42 , 43 ]. Other neurotransmitters were also suggested that could be reduced by BoNT-A injection, including substance P, calcitonin gene-related peptide, and glutamate [ 44 ].…”

Section: Reviewmentioning

confidence: 99%

The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review

Alsaati,

Alsaadoun,

Kinkar

et al. 2023

Cureus

View full text Add to dashboard Cite

The off-label use of botulinum toxin type-A (BoNT-A) in treating rosacea seems encouraging, but the evidence is still lacking regarding its efficacy and safety. This study was conducted to summarize the evidence regarding the efficacy and safety of BoNT-A in the treatment of rosacea patients. A comprehensive literature search was conducted in several databases, and 17 studies were included. Before-after and split-face comparisons showed that BoNT-A significantly alleviated the symptoms of facial erythema and flushing and improved the patient’s quality of life/satisfaction. However, the symptoms recurred three to six months post-injection, requiring repeated treatments in some patients. The pooled rates of post-injection localized erythema, ecchymosis, and facial muscle affection represented 24.6%, 5.1%, and 4.3%, respectively. BoNT-A seems to be effective in alleviating the symptoms of rosacea with a low rate of adverse events. However, the recurrence of the symptoms a few months after the injection requires repeated sessions, which may raise cost-effectiveness issues. Large-scale clinical trials are required to confirm the effectiveness and define the optimal dosing regimen and the rate of recurrence. Future studies should allow for an adequate follow-up after the treatment, with repeated measurements of the outcomes.

show abstract

Botulinum toxin for scalp dysesthesia

Cited by 5 publications

References 7 publications

Successful Treatment of Refractory Trichodynia With Onabotulinumtoxin-A

Successful Treatment of Refractory Trichodynia With Onabotulinumtoxin-A

Botulinum Toxin for Scalp Conditions: A Systematic Review

The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review

Contact Info

Product

Resources

About